Annual Cash & Cash Equivalents
$281.26 M
+$185.63 M+194.11%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual cash & cash equivalents is currently $281.26 million, with the most recent change of +$185.63 million (+194.11%) on 31 December 2023. During the last 3 years, it has risen by +$236.35 million (+526.30%). EYPT annual cash & cash equivalents is now at all-time high.EYPT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$79.83 M
-$10.94 M-12.05%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly cash and cash equivalents is currently $79.83 million, with the most recent change of -$10.94 million (-12.05%) on 30 September 2024. Over the past year, it has dropped by -$53.20 million (-39.99%). EYPT quarterly cash and cash equivalents is now -71.62% below its all-time high of $281.26 million, reached on 31 December 2023.EYPT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +194.1% | -40.0% |
| 3 y3 years | +526.3% | -33.3% |
| 5 y5 years | +521.4% | +151.3% |
EYPT Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +526.3% | -71.6% | +5.9% |
| 5 y | 5 years | at high | +1166.2% | -71.6% | +259.4% |
| alltime | all time | at high | >+9999.0% | -71.6% | +9969.4% |
EyePoint Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $79.83 M(-12.1%) |
| June 2024 | - | $90.77 M(-66.5%) |
| Mar 2024 | - | $271.01 M(-3.6%) |
| Dec 2023 | $281.26 M(+194.1%) | $281.26 M(+111.4%) |
| Sept 2023 | - | $133.03 M(-4.7%) |
| June 2023 | - | $139.60 M(+32.0%) |
| Mar 2023 | - | $105.77 M(+10.6%) |
| Dec 2022 | $95.63 M(-46.5%) | $95.63 M(+26.9%) |
| Sept 2022 | - | $75.36 M(-8.2%) |
| June 2022 | - | $82.13 M(-19.1%) |
| Mar 2022 | - | $101.55 M(-43.1%) |
| Dec 2021 | $178.59 M(+297.7%) | $178.59 M(+49.2%) |
| Sept 2021 | - | $119.71 M(-6.2%) |
| June 2021 | - | $127.63 M(-7.9%) |
| Mar 2021 | - | $138.58 M(+208.6%) |
| Dec 2020 | $44.91 M(+102.2%) | $44.91 M(+56.3%) |
| Sept 2020 | - | $28.73 M(+25.9%) |
| June 2020 | - | $22.81 M(-13.3%) |
| Mar 2020 | - | $26.30 M(+18.4%) |
| Dec 2019 | $22.21 M(-50.9%) | $22.21 M(-30.1%) |
| Sept 2019 | - | $31.76 M(-28.1%) |
| June 2019 | - | $44.16 M(+1.8%) |
| Mar 2019 | - | $43.38 M(-22.2%) |
| Dec 2018 | $45.26 M(+16.7%) | - |
| Sept 2018 | - | $55.76 M(+43.8%) |
| June 2018 | $38.78 M(+129.5%) | $38.78 M(+137.2%) |
| Mar 2018 | - | $16.35 M(+26.9%) |
| Dec 2017 | - | $12.88 M(+8.8%) |
| Sept 2017 | - | $11.83 M(-30.0%) |
| June 2017 | $16.90 M(+10.4%) | $16.90 M(+31.3%) |
| Mar 2017 | - | $12.87 M(+10.1%) |
| Dec 2016 | - | $11.69 M(-18.3%) |
| Sept 2016 | - | $14.31 M(-6.6%) |
| June 2016 | $15.31 M(-19.9%) | $15.31 M(-38.4%) |
| Mar 2016 | - | $24.87 M(+121.8%) |
| Dec 2015 | - | $11.21 M(-20.4%) |
| Sept 2015 | - | $14.09 M(-26.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2015 | $19.12 M(+24.7%) | $19.12 M(-16.9%) |
| Mar 2015 | - | $23.01 M(-22.7%) |
| Dec 2014 | - | $29.75 M(+161.3%) |
| Sept 2014 | - | $11.38 M(-25.8%) |
| June 2014 | $15.33 M(+122.3%) | $15.33 M(-17.4%) |
| Mar 2014 | - | $18.55 M(+21.9%) |
| Dec 2013 | - | $15.22 M(+4.6%) |
| Sept 2013 | - | $14.55 M(+110.8%) |
| June 2013 | $6.90 M(+49.2%) | $6.90 M(-13.7%) |
| Mar 2013 | - | $8.00 M(-15.0%) |
| Dec 2012 | - | $9.41 M(+12.2%) |
| Sept 2012 | - | $8.39 M(+81.4%) |
| June 2012 | $4.63 M(-64.2%) | $4.63 M(-27.5%) |
| Mar 2012 | - | $6.38 M(-24.2%) |
| Dec 2011 | - | $8.41 M(-14.3%) |
| Sept 2011 | - | $9.81 M(-24.0%) |
| June 2011 | $12.91 M(-16.8%) | $12.91 M(-2.9%) |
| Mar 2011 | - | $13.30 M(+31.3%) |
| Sept 2010 | - | $10.13 M(-34.7%) |
| June 2010 | $15.51 M(+124.9%) | $15.51 M(+290.7%) |
| Mar 2010 | - | $3.97 M(-22.6%) |
| Dec 2009 | - | $5.13 M(-14.0%) |
| Sept 2009 | - | $5.96 M(-13.6%) |
| June 2009 | $6.90 M(-55.8%) | $6.90 M(-14.0%) |
| Mar 2009 | - | $8.02 M(-18.6%) |
| Dec 2008 | - | $9.85 M(-10.3%) |
| Sept 2008 | - | $10.98 M(-29.6%) |
| June 2008 | $15.61 M(+484.6%) | $15.61 M(-14.1%) |
| Mar 2008 | - | $18.18 M(+85.8%) |
| Dec 2007 | - | $9.78 M(-40.5%) |
| Sept 2007 | - | $16.45 M(+516.3%) |
| June 2007 | $2.67 M(-76.7%) | $2.67 M(-37.2%) |
| Dec 2006 | - | $4.25 M(-63.0%) |
| June 2006 | $11.47 M(+17.1%) | $11.47 M(+17.1%) |
| June 2005 | $9.79 M(-55.1%) | $9.79 M(-55.1%) |
| June 2004 | $21.79 M(+2647.9%) | $21.79 M(+2647.9%) |
| June 2003 | $792.80 K(-51.8%) | $792.80 K |
| June 2001 | $1.64 M | - |
FAQ
- What is EyePoint Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is EyePoint Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is EyePoint Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of EYPT is $281.26 M
What is the all time high annual cash & cash equivalents for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual cash & cash equivalents is $281.26 M
What is EyePoint Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, EYPT annual cash & cash equivalents has changed by +$185.63 M (+194.11%)
What is EyePoint Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of EYPT is $79.83 M
What is the all time high quarterly cash and cash equivalents for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly cash and cash equivalents is $281.26 M
What is EyePoint Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, EYPT quarterly cash and cash equivalents has changed by -$53.20 M (-39.99%)